Gold futures for June delivery closed down 2.92% on the Comex today. The metal closed at $2343.40 an ounce. The drop came on a lessening of fears that the exchange of attacks between Israel and Iran would quickly lead to a wider Middle East war. And on growing sentiment that the Federal Reserve isn’t likely to cut interest rates soon. The drop in the gold contract for June delivery was the largest since February 3, 2023 when it fell 2.8%.
Today’s Quick Pick is Abbott Laboratories (ABT). The medical device sector is very complicated with constant changes to technology and best practice therapeutics and it can be very hard to keep track of, but two things recently caught my eye about Abbott. The company is generally very conservative and rarely raises guidance, but it did exactly that in its first quarter earnings report. It wasn’t a huge raise but the company went from projecting earnings in a range of $3.20 a share to $3.40 a share to a range with a higher floor of $3.25 to $3.40 a share. The other announcement was a big boost in sales of its diabetes continuous glucose monitoring device, Freestyle Libre. Sales grew to $1.5 billion, up 22.4% year over year. Overall, at the company medical device sales grew 14% year over year, though their Covid test sales were down 18% year over year. I think this is a medical device company that is well-positioned for an aging population. Â The stock pays a 2.08% dividend. Morningstar says this stock trades at fair value with the shares down about 7.8% in the last month. I think this is a good chance to buy this well-managed, conservative company.
It’s been a tough month for Treasuries with yields rising on a re-thinking of when the Federal Reserve might begin to cut interest rates. The yield on the 10-year Treasury closed at 4.62% on Friday. That’s an increase in yield of 35 basis points in a month. (When yields climb, bond prices fall.) And this week the Treasury will auction a combined $183 billion of two-, five- and seven-year Treasury notes. Ans that’s ahead of the latest update on the Personal Consumption Expenditures index, the Federal Reserve’s preferred inflation measure.
I’m sure you’ve noticed. The technology sector, which led the stock market rally in 2023 and in the early days of 2024, is in a slump. The Technology Select Sector SPDR ETF (XLK) tumbled 6.27% last week and is down 7.16% in the last month. For 2024 to date, as of the close on April 19, the sector is at break even with gain of 0.19%. Quite a turnabout for a sector that is still up 30% for the last 12 months. This week brings a raft of tech earnings that could turn the sector’s trend around. Or not.
Today’s Hot Button Moves NOW video is Buy ASML Holding (ASML). ASML is the only global manufacturer of the most cutting-edge chip-making equipment, a technology called Extreme Ultra Violet Lithography (EUV). The equipment allows for a smaller chip, more transistors on the chip, and more power for less silicon. ASML’s earnings report on April 16 was disappointing, with fewer than expected orders, a situation that will likely continue into the next couple of quarters. This resulted in a big drop in earnings and the stock taking a big hit. But, this is the only game in town for this equipment, and anything chip that uses the new 2-nanometer, 3-nanometer, and 5-nanometer technologies will be made on ASML equipment. So orders will not stay down for long. I would use this weakness to buy ASML Holding. It’s not cheap, but it’s not likely not get much cheaper than this, and as geopolitical chip wars settle, orders for ASML will jump rebound. ASML Holding is a member of my long-term 50 Stocks Portolio.
Bookkeeping. I added AbbVie (ABBV) as Pick #10 for My New World for Dividend Investing Special Report (You can find it in the Special Report section of this site along with all the content on this market and its trends for Dividend Income investors. But I’m reposting it as a stand alone pick so no one misses it. AbbVie (ABBV) has been a long-time member of the Dividend Portfolio with a gain of 213% since my January 29, 2020 pick. The question right now is Should it be a top dividend pick going forward? After all, the appreciation in the stock has dropped the dividend yield to 3.67%. (Add in a modest yield from buybacks and the total yield goes to 4.18%.) The most pressing question has been What will replace the $20 billion in annual revenue from the company’s blockbuster arthritis drug Humira (adalimumab) now that it faces competition from biosimilar generics? Now we’ve got some numbers to answer that question and to me they add up to AbbVie remaining a top dividend pick.
Today’s video is Want to know when the Fed will cut rates? Look at the calendar. The Fed only has so many meetings left for 2024 and even fewer if you only coun those with Dot Plot updates of the Fed’s economic projections. The Fed is on the verge of a major shift in policy and the U.S. central bank almost never makes a big policty shift at a meeting without an update of its economic projections.. Early in the year, people were looking for up to five cuts, now, sentiment has shifted to one or fewer. If we get a rate cut at all, when will it be? Look at which upcoming Fed meetings include Dot Plots. The Fed doesn’t like to surprise investors and if they make a drastic change, like a shift to rate cuts, you can bet they want to do it while they’re also discussing projections for 2024 and 2025. The.CME Fedwatch Tool currently odds for the next meeting, May 1, at a 98% chance of no cut and the June meeting is now up to an 84.8% chance of no cut. The June meeting WILL have a Dot Plot and, up until recently, the finanial markets believed that meeting that would deliver the news. Because the Fed generally likes to give in-depth information during a big policy shift, it’s unlikely that the rate cut will be in July, since no dot Plot economic pdate is scheduled for that meeting. The next real chance of a rate cut, I think, is September 18, which has a Dot Plot. (There is no August Fed meeting.) The market thinks there will be a cut in September, and CME Fedwatch has the odds of no cut at that meeting at just 32.7%. A second rate cut in 2024 would have to be at the December 18 meeting, the final 2024 meeting with a Dot Plot. (The Fed doesn’t meet in Ocrober and the November meeting does include a Dot Plot update.) Without the September cut, it’s very unlikely there will be two cuts in 2024. Unless inflation data changes a lot, I doubt we’ll have two rate cuts, but we can look for one in September or December at this point.
China reported faster-than-expected economic growth in the first quarter–but… Although Gross Domestic Product climbed 5.3% in the quarter–a faster rate of growth than in the first quarter of 2023 and above economist estimates, most of the good news came from the first two months of the quarter. In March growth in retail sales slumped and industrial output fell short of forecasts. That doesn’t bode well for the rest of 2024.
Can’t figure Tesla (TSLA) out? Welcome to the club. The stock was down another 5.59% today, April 15, and is now down 31% for 2024. Maybe investors will get some clarity on the company’s identity and strategy when it announced earnings on April 23. Wall Street analysts expect earnings of 36 cents a share against earnings of 73 cents a share in 2023. I think that strategic clarity is actually more important than quarterly earnings at this point for Tesla.
Apple has lost its spot as the world’s biggest mobile phone seller, IDC reported today, April 15. A steep drop in sales in China for Apple let South Korean rival Samsung retake the lead in global market share. Samsung had been the biggest seller of mobile phones for 12 years until the end of 2023, when sales of Apple’s iPhone models overtook it. Global smartphone shipments increased by 8% to 289.4m units during January-March, according to IDC. Samsung has a 20.8% market share. That beat Apple’s 17.3% share
After Israel and its allies (with the help of some Arab states that don’t want to see a wider Middle East war and who aren’t thrilled with the growing power of Iran and its proxies) succeeded in shooting down almost all of the drones (170), ballistic missiles (120), and cruise missiles (30) launched by Iran against the country, will the two sides both declare victory and claim that honor is satisfied or will one or the other escalate the war with another round of attacks? As of early Monday trading in Asia, the oil and gold markets have reacted with concern but not panic. Gold, up 13% already this year to a record above $2,400 an ounce, moved higher but the gains were relatively modest. Spot gold climbed 0.8% to $2,361.92 an ounce as of 6:20 a.m.in Singapore. The global oil market opened to the upside but by less than 1%. And prices have been steady to slightly weaker since then.
All good things come to an end. After seven straight quarters of record levels of profits from net interest income, the spread between what earns by lending and what it pays depositors to raise funds, JPMorgan Chase (JPM) reported that net interest income slightly missed analyst estimates for the first quarter. The quarter the company reported today certainly wasn’t a disaster. The bank earned $23.1 billion in net interest income in the period, up 11% from the first quarter of 2023. But the end of the beat and raise guidance of the last year and a half plus an increase in costs were enough to lead to substantial selling today, April 12. The shares finished the day down 6.47% at $182.79. Analysts and investors were clearly hoping for more.
